DeepMed Research

TORAY INDUSTRIES, INC.

🇹🇼Taiwan

Country: 🇹🇼Taiwan

Ownership: Public

Established: 1926-04-16

Employees: 48.1K

Market Cap: -

Website: http://www.toray.co.jp

Clinical Trials

A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer

Interventions: Biological: TRK-950
Drug: Ramucirumab
Drug: Paclitaxel

First Posted Date: 2023-09-15

Last Posted Date: 2025-03-26

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 146

Registration Number: NCT06038578

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
City of Hope at Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸
University of California, Los Angeles, Santa Monica, California, United States

and more 20 locations

A Study of TRK-950 in Patients with Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor

Interventions: Biological: TRK-950
Drug: Nivolumab

First Posted Date: 2022-06-21

Last Posted Date: 2025-03-17

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 13

Registration Number: NCT05423262

Locations: 🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan

Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)

Not Applicable

Recruiting

Conditions: Acute Respiratory Distress Syndrome

Interventions: Device: NOA-001

First Posted Date: 2021-03-18

Last Posted Date: 2024-07-09

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 45

Registration Number: NCT04804943

Locations: 🇯🇵
Showa University Hospital, Tokyo, Japan

A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)

Phase 2

Withdrawn

Conditions: Chemotherapy-induced Peripheral Neuropathy

Interventions: Drug: TRK-750/Placebo
Drug: Placebo/TRK-750

First Posted Date: 2020-02-25

Last Posted Date: 2022-03-15

Lead Sponsor: Toray Industries, Inc

Registration Number: NCT04282590

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor
Colorectal Cancer
Gastric Cancer
Renal Cell Carcinoma
Melanoma
Epithelial Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
Cholangiocarcinoma
Bladder Cancer

Interventions: Biological: TRK-950
Drug: Irinotecan
Drug: PLD
Drug: Ramucirumab
Drug: Imiquimod Cream
Drug: Gemcitabine
Drug: Nivolumab
Drug: Leucovorin
Drug: Paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Drug: Pembrolizumab
Drug: Bevacizumab
Drug: 5-FU

First Posted Date: 2019-03-13

Last Posted Date: 2025-04-09

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 187

Registration Number: NCT03872947

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
AOA-HOPE, Tucson, Arizona, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 11 locations

Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: TRK-250

First Posted Date: 2018-11-01

Last Posted Date: 2023-10-23

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 34

Registration Number: NCT03727802

Locations: 🇺🇸
Advanced Pulmonary & Sleep Research Institute of Florida, Daytona Beach, Florida, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States

and more 8 locations

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750

Phase 1

Completed

Conditions: Healthy, Peripheral Neuropathic Pain

Interventions: Drug: Placebo
Drug: TRK-750

First Posted Date: 2017-11-17

Last Posted Date: 2018-12-19

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 105

Registration Number: NCT03346330

Locations: 🇬🇧
London, London, United Kingdom

TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TRK-700
Drug: Midazolam
Drug: Digoxin

First Posted Date: 2017-02-03

Last Posted Date: 2017-10-25

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 48

Registration Number: NCT03043248

Locations: 🇯🇵
Tokyo, Tokyo, Japan

TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus

Phase 1

Completed

Conditions: Uremic Pruritus

Interventions: Drug: TRK-820

First Posted Date: 2016-12-23

Last Posted Date: 2017-07-21

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 23

Registration Number: NCT03002233

Locations: 🇩🇪
Germany, Germany, Germany
🇧🇬
Bulgaria, Bulgaria, Bulgaria

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced or Metastatic Solid Carcinomas
Colon Cancer
Cholangiocarcinoma

Interventions: Biological: TRK-950

First Posted Date: 2016-12-13

Last Posted Date: 2025-04-16

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 38

Registration Number: NCT02990481

Locations: 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇫🇷
Centre Léon Bérard, Lyon, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy